MODERN DIAGNOSTIC MARKERS OF LIVER FIBROSIS IN CHILDREN WITH CHRONIC VIRAL HEPATITIS B AND C
DOI:
https://doi.org/10.32689/2663-0672-2023-2-2Keywords:
markers of fibrogenesis (FABP-1, Arginase-1, YKL-40), children and adolescents, chronic viral hepatitis B and C, liver fibrosis, jaundice.Abstract
Abstract. The article contains scientific data about modern markers of liver fibrosis in children with chronic viral hepatitis B and C such as: FABP-1-L, arginase-1 and YKL-40. The aim of study: to evaluate the level of arginase-1 in children with chronic viral hepatitis B and C. Material and methods: 40 patients with diagnoses of chronic viral hepatitis B and C (mean age – 11,48±0,6 years) were examined. All patients underwent of collecting of anamnesis, clinical examination, determination of the degree of liver fibrosis. Level of arginase-1 was performed by ELISA. Data analysis was performed using the software package “Statistica 8.0”. The reliability of the data difference was established by paired Student's t-test. The difference was considered significant at p<0,05. Results: In examined patients of study group level of Arg-1 was significant higher (108,58±4,9 ng/ml) compared with patients of control group (76,48±6,09 ng/ml) (p<0,001). Arg-1 level in male representatives was higher in both groups. Level of Arg-1 among patients of study and control group increased with increasing of patients’ age. The level of Arg-1 in children of study group with oncological diseases was higher (115,24±6,2 ng/ml), compared with children without this factor (96,22±7,14 ng/ml). Level of Arg-1 was significant higher in patients with liver fibrosis F0 (124,07±7,7 ng/ml; p<0,001), F1 (106,55±0,15 ng/ml; p<0,001), F1-2 (106,07±8,5 ng/ml; p<0,01), F2 (89,44 ng/ml; p<0,05) compared with control group (76,48±6,09 ng/ml). Correlation between Arg-1 level and liver fibrosis degree was detected among patients of study group (R=-0,49; p=0,001). Conclusion: Arginase-1 – important marker that should be studied by scientists nowadays to understand the pathogenesis of fibrogenesis of the liver.
References
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L., Papatheodoridis, G., ... & Tacke, F. (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology, 67(2), 370–398.
Yapali, S., Talaat, N., & Lok, A. S. (2014). Management of hepatitis B: our practice and how it relates to the guidelines. Clinical gastroenterology and hepatology, 12(1), 16–26.
Indolfi, G., Easterbrook, P., Dusheiko, G., El-Sayed, M. H., Jonas, M. M., Thorne, C., ... & Penazzato, M. (2019). Hepatitis C virus infection in children and adolescents. The lancet Gastroenterology & hepatology, 4(6), 477–487.
Modin, L., Arshad, A., Wilkes, B., Benselin, J., Lloyd, C., Irving, W. L., & Kelly, D. A. (2019). Epidemiology and natural history of hepatitis C virus infection among children and young people. Journal of hepatology, 70(3), 371–378.
Sun, Y., Wu, X., Zhou, J., Meng, T., Wang, B., Chen, S., ... & You, H. (2020). Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clinical Gastroenterology and Hepatology, 18(11), 2582–2591.
Deng, Y., Li, G., Chang, D., & Su, X. (2020). YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases. Clinica Chimica Acta, 511, 40–46.
Tizaoui, K., Yang, J. W., Lee, K. H., Kim, J. H., Kim, M., Yoon, S., ... & Smith, L. (2022). The role of YKL-40 in the pathogenesis of autoimmune diseases: A comprehensive review. URL: https://ir.ymlib.yonsei.ac.kr/handle/22282913/188616
Guan, R., Lin, R., Jin, R., Lu, L., Liu, X., Hu, S., & Sun, L. (2020). Chitinase-like protein YKL-40 regulates human bronchial epithelial cells proliferation, apoptosis, and migration through TGF-β1/Smads pathway. Human & Experimental Toxicology, 39(4), 451–463.
Zhang, Z., Wang, H., Yan, Z., & Zhu, K. (2022). Up-regulated YKL-40 is associated with poor prognosis of hepatocellular carcinoma patients with hepatitis B-related cirrhosis. Archives of Medical Science. DOI: https://doi.org/10.5114/aoms/141821
Bielawski, K., Rhone, P., Bulsa, M., & Ruszkowska-Ciastek, B. (2020). Pre-operative combination of normal BMI with elevated YKL-40 and leptin but lower adiponectin level is linked to a higher risk of breast cancer relapse: A report of four-year follow-up study. Journal of Clinical Medicine, 9(6), 1742.
Wang, J., Qi, S., Zhu, Y. B., & Ding, L. (2022). Prognostic value of YKL-40 in colorectal carcinoma patients: A metaanalysis. World Journal of Clinical Cases, 10(7), 2184.
Yamamoto N, Sugimoto K, Murata K, Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCVassociated liver disease. World J Gastroenterol 2005; 11(4): 476–481 http://www.wjgnet.com/1007-9327/11/476.asp
Del Turco, S., De Simone, P., Ghinolfi, D., Gaggini, M., & Basta, G. (2021). Comparison between galectin-3 and YKL-40 levels for the assessment of liver fibrosis in cirrhotic patients. Arab Journal of Gastroenterology, 22(3), 187–192.
Kwon Y, Kim JH, Ha EK, Jee HM, Baek HS, Han MY, Jeong SJ. Serum YKL-40 Levels Are Associated with the Atherogenic Index of Plasma in Children. Mediators Inflamm. 2020 Sep 26;2020:8713908. doi: 10.1155/2020/8713908. PMID: 33061832; PMCID: PMC7533750
Milner, K.-L., van der Poorten, D., Xu, A., Bugianesi, E., Kench, J.G., Lam, K.S.L., Chisholm, D.J. and George, J. (2009), Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology, 49: 1926–1934. https://doi.org/10.1002/hep.22896
Li, H.-L., Wu, X., Xu, A., & Hoo, R. L.-C. (2021). A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update. International Journal of Molecular Sciences, 22(17), 9386. https://doi.org/10.3390/ijms22179386
Pillai, S. S., Lakhani, H. V., Zehra, M., Wang, J., Dilip, A., Puri, N., ... & Sodhi, K. (2020). Predicting nonalcoholic fatty liver disease through a panel of plasma biomarkers and microRNAs in female West Virginia population. International Journal of Molecular Sciences, 21(18), 6698
Rakela, J. L., Karvellas, C. J., Koch, D. G., Vegunta, S., & Lee, W. M. (2023). Acute Liver Failure: Biomarkers Evaluated by the Acute Liver Failure Study Group. Clinical and Translational Gastroenterology, 14(4).
Watt, J., Kurth, M. J., Reid, C. N., Lamont, J. V., Fitzgerald, P., & Ruddock, M. W. (2022). Non-alcoholic fatty liver disease – A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease. Frontiers in Physiology, 13, 963513
Eguchi, A., & Iwasa, M. (2021). The role of elevated liver-type fatty acid-binding proteins in liver diseases. Pharmaceutical Research, 38, 89–95.
Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, et al. (2009) Arginase-1–Expressing Macrophages Suppress Th2 Cytokine–Driven Inflammation and Fibrosis. PLoS Pathog 5(4): e1000371. doi:10.1371/journal.ppat.1000371
Kitowska, K., Zakrzewicz, D., Konigshoff, M., Chrobak, I., Grimminger, F., Seeger, W., ... & Eickelberg, O. (2008). Functional role and species-specific contribution of arginases in pulmonary fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology, 294(1), L34–L45.
Chrzanowska, A., Gajewska, B., & Barańczyk-Kuźma, A. (2009). Arginase isoenzymes in human cirrhotic liver. Acta Biochimica Polonica, 56(3), 465–469.
